Heterologous Boosting With<i>Listeria</i>-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection

Si-Jing Liu,Si-Cheng Tian,Yun-Wen Zhang,Tian Tang,Ju-Mei Zeng,Xiao-Yong Fan,Chuan Wang
DOI: https://doi.org/10.3389/fimmu.2020.02036
IF: 7.3
2020-01-01
Frontiers in Immunology
Abstract:While Baccillus Calmette-Guerin (BCG) is used worldwide, tuberculosis (TB) is still a global concern due to the poor efficacy of BCG. Novel vaccine candidates are therefore urgently required. In this study, two attenuated recombinantListeriastrains, LM Delta-msvand LI Delta-msvwere constructed by deletion ofactAandplcBand expression of a fusion protein consisting of T cell epitopes from fourMycobacterium tuberculosis(Mtb) antigens (Rv2460c, Rv2660c, Rv3875, andRv3804c). The safety and immunogenicity of the two recombinant strains were evaluated in C57BL/6J mice. After intravenous immunization individually, both recombinant strains entered liver and spleen but eventually were eliminated from these organs after several days. Simultaneously, they induced antigen-specific cell-mediated immunity, indicating that the recombinantListeriastrains were immunogenic and safein vivo. LM Delta-msvimmunization induced stronger cellular immune responses than LI Delta-msvimmunization, and when boosted with LI Delta-msv, antigen-specific IFN-gamma CD8(+)T cell responses were notably magnified. Furthermore, we evaluated the protection conferred by the vaccine candidates against mycobacterial infection via challenging the mice with 1 x 10(7)CFU of BCG. Especially, we tested the feasibility of application of them as heterologous BCG supplement vaccine by immunization of mice with BCG firstly, and boosted with LM Delta-msvand LI Delta-msvsequentially before challenging. Combination immune strategy (LM Delta-msvprime-LI Delta-msvboost) conferred comparable protection efficacy as BCG alone. More importantly, BCG-vaccinated mice acquired stronger resistance to Mycobacterial challenge when boosted with LM Delta-msvand LI Delta-msvsequentially. Our results inferred that heterologous immunization withListeria-based recombinant strains boosted BCG-primed protection against pulmonary mycobacterial infection.
What problem does this paper attempt to address?